Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07399132 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of APL-10456-Vaccine

StatusActive, Not Recruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Aug 2, 2026 to May 18, 2027
    • Trial status changed: Recruiting → Active, Not Recruiting
    • Study completion moved earlier from Oct 21, 2027 to May 18, 2027
    • Site details revised at 2 of 2 sites
    v4
  2. Study sites: 1 to 2v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Feb 9, 2026 to Feb 16, 2026
    • Study title shortened, about 1 word
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AP09CP01 is a Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study which is conducted in Australia. The main purpose of this research study is to evaluate the safety, side effects, and immune response of APL-10456-Vaccine, a Rhinovirus (RV) Vaccine, when compared with a placebo in Younger and Older Healthy Volunteers
Trial Details
NCT Number NCT07399132
Lead Sponsor Apollo Therapeutics Ltd
Conditions
(from sponsor)		 Rhinovirus
Enrollment 144 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov